首页 > 最新文献

Ayu最新文献

英文 中文
Festivals of Ayurveda: Scope and challenges. 阿育吠陀的节日:范围与挑战。
Ayu
Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI: 10.4103/ayu.ayu_18_23
K R Bhavana

Background: One of the main ingredients to put human societies glued together is celebrating the festivals. Festivals are the markers of scientific achievements and historic milestones. Moreover, celebrating festival ensures the continuation of tradition. The number of festivals celebrating Ayurveda are, however, very few. Festivals bring pomp and glory in lives and are a way of expressing gratitude to the legends for bringing out the deepest meanings of the cosmos.

Aim: To revive the lost tradition of Ayurvedic festivals, the study was undertaken.

Material and methods: Ayurvedic scriptures and Puranas were carefully reviewed to find festivals associated with Ayurveda. The paper reviews the specific dates and the method of celebration of few festivals associated with Ayurveda such as Dhanvantari Jayanti, Brahma Puja, Shakrotsava, Kaumudi Mahotsava, Madana Trayodashi, Charaka Jayanti, Kubera Mahotsava, Varuna Mahotsava, and Yamadamshtra. Dhanvantari Jayanti as National Ayurveda Day has already gained popularity.

Result: Festivals foster national cohesiveness, promote communal harmony, preserve family values, revitalize the economy, and foster cultural and, in this scenario, even medical tourism. However, globalizing these festivals is challenging due to difference in calendars.

Conclusion: Celebrating festivals have deep Yogic meaning. It helps to maintain national identity. The yearly seasonal cycles affect the physical and mental health of humans. Hence, there is a need to revive the traditional Ayurvedic festivals.

背景:庆祝节日是凝聚人类社会的主要因素之一。节日是科学成就和历史里程碑的标志。此外,庆祝节日还能确保传统的延续。然而,庆祝阿育吠陀的节日却很少。目的:为了恢复阿育吠陀节这一失传的传统,我们开展了这项研究:材料和方法:仔细查阅了阿育吠陀经文和古兰经,以找到与阿育吠陀相关的节日。本文回顾了与阿育吠陀相关的几个节日的具体日期和庆祝方法,如 Dhanvantari Jayanti、Brahma Puja、Shakrotsava、Kaumudi Mahotsava、Madana Trayodashi、Charaka Jayanti、Kubera Mahotsava、Varuna Mahotsava 和 Yamadamshtra。Dhanvantari Jayanti 作为 "全国阿育吠陀日 "已经广受欢迎:结果:节日可以增强民族凝聚力,促进社区和谐,维护家庭价值观,振兴经济,促进文化旅游,在这种情况下,甚至还可以促进医疗旅游。然而,由于历法不同,这些节日的全球化具有挑战性:庆祝节日具有深刻的瑜伽意义。它有助于保持民族特性。每年的季节循环影响着人类的身心健康。因此,有必要恢复传统的阿育吠陀节。
{"title":"Festivals of Ayurveda: Scope and challenges.","authors":"K R Bhavana","doi":"10.4103/ayu.ayu_18_23","DOIUrl":"https://doi.org/10.4103/ayu.ayu_18_23","url":null,"abstract":"<p><strong>Background: </strong>One of the main ingredients to put human societies glued together is celebrating the festivals. Festivals are the markers of scientific achievements and historic milestones. Moreover, celebrating festival ensures the continuation of tradition. The number of festivals celebrating Ayurveda are, however, very few. Festivals bring pomp and glory in lives and are a way of expressing gratitude to the legends for bringing out the deepest meanings of the cosmos.</p><p><strong>Aim: </strong>To revive the lost tradition of Ayurvedic festivals, the study was undertaken.</p><p><strong>Material and methods: </strong>Ayurvedic scriptures and <i>Puranas</i> were carefully reviewed to find festivals associated with Ayurveda. The paper reviews the specific dates and the method of celebration of few festivals associated with Ayurveda such as <i>Dhanvantari Jayanti, Brahma Puja, Shakrotsava, Kaumudi Mahotsava, Madana Trayodashi, Charaka Jayanti, Kubera Mahotsava, Varuna Mahotsava</i>, and <i>Yamadamshtra. Dhanvantari Jayanti</i> as National Ayurveda Day has already gained popularity.</p><p><strong>Result: </strong>Festivals foster national cohesiveness, promote communal harmony, preserve family values, revitalize the economy, and foster cultural and, in this scenario, even medical tourism. However, globalizing these festivals is challenging due to difference in calendars.</p><p><strong>Conclusion: </strong>Celebrating festivals have deep Yogic meaning. It helps to maintain national identity. The yearly seasonal cycles affect the physical and mental health of humans. Hence, there is a need to revive the traditional Ayurvedic festivals.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial. COROPROTECT 套件作为治疗轻度至中度 COVID-19 的附加疗法的安全性和有效性:随机安慰剂对照试验。
Ayu
Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI: 10.4103/ayu.ayu_92_22
Chetan Savaliya, Shridhar Pandya, Kamalesh Thumar, Dheeraj Nagore

Background: The constructive role of Ayurveda in managing COVID-19 has been widely discussed, with identified herbs showing immunomodulatory and anti-viral potential. However, clinical trials examining their safety and efficacy are limited.

Aim: The aim of this study is to determine the efficacy of COROPROTECT kit, a proprietary Ayurvedic formulation, in COVID-19.

Materials and method: Randomized, placebo-controlled trial with 312 mild to moderate hospitalized COVID-19 patients. Groups received COROPROTECT or placebo for 10 days alongside standard care.

Results: The outcome measures included the number of days taken to reverse the reverse transcriptase-polymerase chain reaction (RT-PCR) status, reduction in symptoms and inflammatory markers. Fisher exact test was used to analyze the changes between categorical variables, whereas the comparative effect of therapy in both groups on inflammatory markers and safety biochemical parameters was analyzed using Student's t test. A total of 300 patients completed the study without any adverse events. The COROPROTECT kit group exhibited a statistically significant higher percentage of patients testing negative on days 4, 7, and 10 compared to the placebo group. A within group analysis showed that trial group to significantly reduced the levels of C-reactive protein (P = 0.03), lactate dehydrogenase (P < 0.001), and interleukin-6 (P = 0.01). Subjects of the trial group experienced complete relief from cough (69.33%), breathlessness (65.33%), and fatigue (62.67%) within 4 days. In contrast, the placebo group had 20%-40% of participants with mild symptoms persisting until day 10.

Conclusion: This study suggests potential future implications, indicating a faster RT-PCR negativity, reduced COVID-19 severity, and inflammatory markers, along with early symptomatic recovery. The COROPROTECT kit proved safe, facilitating an accelerated clinical recovery compared to conventional care.

背景:阿育吠陀在控制 COVID-19 方面的建设性作用已被广泛讨论,已确定的草药具有免疫调节和抗病毒潜力。目的:本研究旨在确定COROPROTECT试剂盒(一种阿育吠陀专利配方)对COVID-19的疗效:随机安慰剂对照试验,312名轻度至中度住院COVID-19患者参加。各组接受 COROPROTECT 或安慰剂治疗 10 天,同时接受标准护理:结果测量包括逆转录酶聚合酶链反应(RT-PCR)状态逆转所需的天数、症状和炎症标志物的减少。费舍尔精确检验用于分析分类变量之间的变化,而两组治疗对炎症指标和安全生化指标的比较效果则采用学生 t 检验进行分析。共有 300 名患者完成了研究,未出现任何不良反应。与安慰剂组相比,COROPROTECT试剂盒组在第4、7和10天检测结果呈阴性的患者比例明显更高。组内分析显示,试验组显著降低了 C 反应蛋白(P = 0.03)、乳酸脱氢酶(P < 0.001)和白细胞介素-6(P = 0.01)的水平。试验组受试者在 4 天内完全缓解了咳嗽(69.33%)、呼吸困难(65.33%)和疲劳(62.67%)。相比之下,安慰剂组有 20%-40% 的受试者轻微症状持续到第 10 天:这项研究表明,RT-PCR 阴性反应更快,COVID-19 严重程度和炎症标志物降低,症状也能尽早恢复。事实证明,COROPROTECT 套件是安全的,与传统治疗相比,它能加快临床康复。
{"title":"Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial.","authors":"Chetan Savaliya, Shridhar Pandya, Kamalesh Thumar, Dheeraj Nagore","doi":"10.4103/ayu.ayu_92_22","DOIUrl":"https://doi.org/10.4103/ayu.ayu_92_22","url":null,"abstract":"<p><strong>Background: </strong>The constructive role of Ayurveda in managing COVID-19 has been widely discussed, with identified herbs showing immunomodulatory and anti-viral potential. However, clinical trials examining their safety and efficacy are limited.</p><p><strong>Aim: </strong>The aim of this study is to determine the efficacy of COROPROTECT kit, a proprietary Ayurvedic formulation, in COVID-19.</p><p><strong>Materials and method: </strong>Randomized, placebo-controlled trial with 312 mild to moderate hospitalized COVID-19 patients. Groups received COROPROTECT or placebo for 10 days alongside standard care.</p><p><strong>Results: </strong>The outcome measures included the number of days taken to reverse the reverse transcriptase-polymerase chain reaction (RT-PCR) status, reduction in symptoms and inflammatory markers. Fisher exact test was used to analyze the changes between categorical variables, whereas the comparative effect of therapy in both groups on inflammatory markers and safety biochemical parameters was analyzed using Student's <i>t</i> test. A total of 300 patients completed the study without any adverse events. The COROPROTECT kit group exhibited a statistically significant higher percentage of patients testing negative on days 4, 7, and 10 compared to the placebo group. A within group analysis showed that trial group to significantly reduced the levels of C-reactive protein (<i>P</i> = 0.03), lactate dehydrogenase (<i>P</i> < 0.001), and interleukin-6 (<i>P</i> = 0.01). Subjects of the trial group experienced complete relief from cough (69.33%), breathlessness (65.33%), and fatigue (62.67%) within 4 days. In contrast, the placebo group had 20%-40% of participants with mild symptoms persisting until day 10.</p><p><strong>Conclusion: </strong>This study suggests potential future implications, indicating a faster RT-PCR negativity, reduced COVID-19 severity, and inflammatory markers, along with early symptomatic recovery. The COROPROTECT kit proved safe, facilitating an accelerated clinical recovery compared to conventional care.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of checkerboard assay to determine the synergy between essential oils extracted from leaves of Aegle marmelos (L.) Correa and nystatin against Candida albicans. 使用棋盘测定法确定从 Aegle marmelos (L.) Correa 叶子中提取的精油与奈司他丁对白色念珠菌的协同作用。
Ayu
Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI: 10.4103/ayu.ayu_397_21
Pramod Ananda Kamble, Manju Phadke

Background: Candida albicans is one of the most common pathogenic yeasts, responsible for causing candidiasis. The use of conventional antifungal agents for the treatment of Candida is reported to be less effective and hence alternative therapies for the treatment are needed. Essential oils of medicinal plants may serve as a strong candidate for natural products in modern therapies.

Aim: The aim of this study was to determine the synergistic potential of essential oils extracted from leaves of Aegle marmelos (L.) Correa and a potent antifungal agent, nystatin, against three clinical isolates of C. albicans using checkerboard assay.

Materials and methods: The antifungal activity of the essential oils of A. marmelos was screened against test cultures by disc diffusion technique. Antibiograms of the test organisms were developed. To determine the minimum fungicidal concentration of the essential oil and nystatin, the broth microdilution method was employed, and a checkerboard assay was used to investigate the synergistic potential of the essential oil and nystatin against the clinical isolates under study. The data were expressed as mean ± standard deviation.

Results: The Σ fractional inhibitory concentration values were calculated as 0.12, 0.37, and 0.28 for three different strains of C. albicans used, respectively, which was <0.5, therefore, the synergy was demonstrated between essential oils and nystatin against the test cultures.

Conclusions: Combinatorial therapy of the essential oils extracted from the leaves of A. marmelos and nystatin may be considered a line of treatment for candidal infections.

背景:白色念珠菌是最常见的致病酵母菌之一,可导致念珠菌病。据报道,使用传统抗真菌剂治疗念珠菌效果不佳,因此需要采用替代疗法进行治疗。目的:本研究的目的是利用棋盘试验确定从 Aegle marmelos (L.) Correa 叶子中提取的精油与强效抗真菌剂奈司他丁对三种临床分离的白色念珠菌的协同作用潜力:材料和方法:采用光盘扩散技术筛选芒果精油对试验培养物的抗真菌活性。绘制了测试生物的抗生素图谱。为了确定精油和硝司他丁的最低杀菌浓度,采用了肉汤微量稀释法,并使用棋盘试验来研究精油和硝司他丁对所研究的临床分离菌的协同潜力。数据以均数±标准偏差表示:结果:对三种不同的白僵菌菌株的Σ分数抑制浓度值分别为 0.12、0.37 和 0.28:从芒果叶中提取的精油与奈司他丁的组合疗法可被视为念珠菌感染的一种治疗方法。
{"title":"Use of checkerboard assay to determine the synergy between essential oils extracted from leaves of <i>Aegle marmelos</i> (L.) Correa and nystatin against <i>Candida albicans</i>.","authors":"Pramod Ananda Kamble, Manju Phadke","doi":"10.4103/ayu.ayu_397_21","DOIUrl":"https://doi.org/10.4103/ayu.ayu_397_21","url":null,"abstract":"<p><strong>Background: </strong><i>Candida albicans</i> is one of the most common pathogenic yeasts, responsible for causing candidiasis. The use of conventional antifungal agents for the treatment of <i>Candida</i> is reported to be less effective and hence alternative therapies for the treatment are needed. Essential oils of medicinal plants may serve as a strong candidate for natural products in modern therapies.</p><p><strong>Aim: </strong>The aim of this study was to determine the synergistic potential of essential oils extracted from leaves of <i>Aegle marmelos</i> (L.) Correa and a potent antifungal agent, nystatin, against three clinical isolates of <i>C. albicans</i> using checkerboard assay.</p><p><strong>Materials and methods: </strong>The antifungal activity of the essential oils of <i>A. marmelos</i> was screened against test cultures by disc diffusion technique. Antibiograms of the test organisms were developed. To determine the minimum fungicidal concentration of the essential oil and nystatin, the broth microdilution method was employed, and a checkerboard assay was used to investigate the synergistic potential of the essential oil and nystatin against the clinical isolates under study. The data were expressed as mean ± standard deviation.</p><p><strong>Results: </strong>The Σ fractional inhibitory concentration values were calculated as 0.12, 0.37, and 0.28 for three different strains of <i>C. albicans</i> used, respectively, which was <0.5, therefore, the synergy was demonstrated between essential oils and nystatin against the test cultures.</p><p><strong>Conclusions: </strong>Combinatorial therapy of the essential oils extracted from the leaves of <i>A. marmelos</i> and nystatin may be considered a line of treatment for candidal infections.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Pharmacognostic study of market samples of Tagara collected from five different markets of Kerala with the official source plant Valeriana jatamansi Jones ex Roxb. 从喀拉拉邦五个不同市场采集的 Tagara 与官方来源植物 Valeriana jatamansi Jones ex Roxb.
Ayu
Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI: 10.4103/ayu.ayu_361_21
P Mohammed Iqbal, C M Harinarayanan, Vivek Palengara

Background: Tagara is a very popular Ayurveda herb used in the treatment insomnia, epilepsy, neurosis, hepatoprotective, anticancerous, and analgesic. Characteristic smell is the typical feature of it. As per the Ayurvedic Pharmacopoeia of India and many other classical texts, rhizomes of Valeriana jatamansi of the family Valerianceae is the accepted source of the drug. From some of the reports from early 1980s, it was found that roots of some aquatic plants such as Nymphoides macrospermum, Nymphoides hydrophylla, Nymphoides indica, and Limnanthemum cristatum were said to be used as Tagara instead of V. jatamansi in the South Indian markets.

Aim: This study proposed to assess the present status of Tagara available in herbal raw drug markets of Kerala.

Materials and methods: Five market samples of Tagara were collected from selected markets of Kerala, and some of the reported aquatic plants, collected from natural habitats nearby. Macroscopic, microscopic, histochemical, and powder microscopic characterization of all these samples were done as per the standard procedure mentioned in Ayurvedic Pharmacopoeia of India and characters observed were compared with official source plant and pharmacopoeial standard.

Results: Morphological characters of market samples of Tagara collected from the various markets of Kerala were not matching with the rhizomes of genuine drug V. jatamansi and that of Uttarakhand sample. The microscopic and histochemical examination also gave the same result. However, these samples showed similarities with the roots of Nymphoides macrospermam. Sample collected from Uttarakhand was the rhizome of V. jatamansi.

Conclusion: The collected market samples of Tagara from various Kerala markets were not the rhizomes of V. jatamansi but the roots of N. macrospermam.

背景介绍Tagara 是一种非常受欢迎的阿育吠陀草药,用于治疗失眠、癫痫、神经衰弱、保肝、抗癌和镇痛。独特的气味是它的典型特征。根据《印度阿育吠陀药典》和许多其他经典文献,缬草科植物缬草的根茎是公认的药物来源。从 20 世纪 80 年代初的一些报告中发现,在南印度市场上,一些水生植物(如 Nymphoides macrospermum、Nymphoides hydrophylla、Nymphoides indica 和 Limnanthemum cristatum)的根据说被用作 Tagara,而不是 V. jatamansi:从喀拉拉邦的选定市场收集了五份 Tagara 的市场样本,并从附近的自然栖息地收集了一些已报道的水生植物。按照《印度阿育吠陀药典》中提到的标准程序,对所有这些样本进行了宏观、显微、组织化学和粉末显微鉴定,并将观察到的特征与官方来源植物和药典标准进行了比较:结果:从喀拉拉邦各个市场采集的 Tagara 样品的形态特征与真正药物 V. jatamansi 的根茎和北阿坎德邦的样本不符。显微镜和组织化学检查也得出了相同的结果。不过,这些样本显示与 Nymphoides macrospermam 的根相似。从北阿坎德邦采集的样本是 V. jatamansi 的根茎:从喀拉拉邦各个市场采集的 Tagara 样品不是 V. jatamansi 的根茎,而是 N. macrospermam 的根。
{"title":"Comparative Pharmacognostic study of market samples of <i>Tagara</i> collected from five different markets of Kerala with the official source plant <i>Valeriana jatamansi</i> Jones ex Roxb.","authors":"P Mohammed Iqbal, C M Harinarayanan, Vivek Palengara","doi":"10.4103/ayu.ayu_361_21","DOIUrl":"https://doi.org/10.4103/ayu.ayu_361_21","url":null,"abstract":"<p><strong>Background: </strong><i>Tagara</i> is a very popular Ayurveda herb used in the treatment insomnia, epilepsy, neurosis, hepatoprotective, anticancerous, and analgesic. Characteristic smell is the typical feature of it. As per the Ayurvedic Pharmacopoeia of India and many other classical texts, rhizomes of <i>Valeriana jatamansi</i> of the family <i>Valerianceae</i> is the accepted source of the drug. From some of the reports from early 1980s, it was found that roots of some aquatic plants such as <i>Nymphoides macrospermum, Nymphoides hydrophylla, Nymphoides indica</i>, and <i>Limnanthemum cristatum</i> were said to be used as <i>Tagara</i> instead of <i>V. jatamansi</i> in the South Indian markets.</p><p><strong>Aim: </strong>This study proposed to assess the present status of <i>Tagara</i> available in herbal raw drug markets of Kerala.</p><p><strong>Materials and methods: </strong>Five market samples of <i>Tagara</i> were collected from selected markets of Kerala, and some of the reported aquatic plants, collected from natural habitats nearby. Macroscopic, microscopic, histochemical, and powder microscopic characterization of all these samples were done as per the standard procedure mentioned in Ayurvedic Pharmacopoeia of India and characters observed were compared with official source plant and pharmacopoeial standard.</p><p><strong>Results: </strong>Morphological characters of market samples of <i>Tagara</i> collected from the various markets of Kerala were not matching with the rhizomes of genuine drug <i>V. jatamansi</i> and that of Uttarakhand sample. The microscopic and histochemical examination also gave the same result. However, these samples showed similarities with the roots of <i>Nymphoides macrospermam</i>. Sample collected from Uttarakhand was the rhizome of <i>V. jatamansi</i>.</p><p><strong>Conclusion: </strong>The collected market samples of <i>Tagara</i> from various Kerala markets were not the rhizomes of <i>V. jatamansi</i> but the roots of <i>N. macrospermam</i>.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge, practice, and challenges of diabetes foot care among patients at the University of Benin Teaching Hospital, Benin City: A cross-sectional study. 贝宁市贝宁大学教学医院患者对糖尿病足护理的认识、实践和挑战:一项横断面研究。
Ayu
Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI: 10.4103/ayu.ayu_282_22
Rosemary Ngozi Osunde, Olaolorunpo Olorunfemi

Background: Foot ulcer is a common complication of diabetes and the most devastating component of diabetes progression that is associated with high morbidity and mortality.

Aims: The aim of this study was to assess the knowledge, practice, and challenges of diabetes foot care among patients with diabetes mellitus.

Materials and methods: This descriptive cross-sectional study assessed knowledge and practice of foot care among type I and type II patients with diabetes attending the University of Benin Teaching Hospital, Benin City. The instrument for data collection was a structured questionnaire with a reliability of 0.880. SPSS version 22 was used to analyze the data.

Results: The findings revealed that there is good knowledge of foot care, among 110 (50.0%) of the diabetic patients, while the practice of foot care was found to be poor among diabetic patients. It also shows the factor that statistically predicts the development of foot ulcers to include combined diet + oral medications + insulin treatment regimen (adjusted odds ratio [AOR] = 0.181, P = 0.016, confidence interval [CI] = 0.045-0.728), history of renal conditions (AOR = 0.115, P = 0.036, CI = 0.015-0.871), not receiving foot care education (AOR = 116.098, P < 0.001, CI = 12.497-1078.554), and receiving foot care education from nurses (AOR = 0.022, P = 0.001, CI = 0.002-0.216). Furthermore, 201 (91.4%) diabetes patients reported fatigue from completing the same task repeatedly, and 198 (90.0%) reported forgetfulness as obstacles to practicing foot care.

Conclusion: When creating DM Patients future care plans, nurses and other health-care administrators must take into account the difficulties and predicting factors related to the practice of diabetes foot care.

背景:足部溃疡是糖尿病的常见并发症,也是糖尿病恶化过程中最具破坏性的部分,与高发病率和高死亡率相关:这项描述性横断面研究评估了在贝宁市贝宁大学教学医院就诊的 I 型和 II 型糖尿病患者的足部护理知识和实践。数据收集工具为结构化问卷,信度为 0.880。数据分析采用 SPSS 22 版本:调查结果显示,110 名糖尿病患者(50.0%)对足部护理有较好的了解,但糖尿病患者的足部护理实践较差。结果还显示,从统计学角度预测足部溃疡发生的因素包括饮食+口服药物+胰岛素联合治疗方案(调整后的几率比[AOR] = 0.181,P = 0.016,置信区间[CI] = 0.045-0.728)、肾病史(AOR = 0.115,P = 0.036,CI = 0.015-0.871)、未接受足部护理教育(AOR = 116.098,P <0.001,CI = 12.497-1078.554)和接受护士足部护理教育(AOR = 0.022,P = 0.001,CI = 0.002-0.216)。此外,201 名糖尿病患者(91.4%)表示重复完成同一任务会感到疲劳,198 名糖尿病患者(90.0%)表示健忘是进行足部护理的障碍:护士和其他医疗管理人员在制定 DM 患者未来护理计划时,必须考虑到与糖尿病足护理实践相关的困难和预测因素。
{"title":"Knowledge, practice, and challenges of diabetes foot care among patients at the University of Benin Teaching Hospital, Benin City: A cross-sectional study.","authors":"Rosemary Ngozi Osunde, Olaolorunpo Olorunfemi","doi":"10.4103/ayu.ayu_282_22","DOIUrl":"https://doi.org/10.4103/ayu.ayu_282_22","url":null,"abstract":"<p><strong>Background: </strong>Foot ulcer is a common complication of diabetes and the most devastating component of diabetes progression that is associated with high morbidity and mortality.</p><p><strong>Aims: </strong>The aim of this study was to assess the knowledge, practice, and challenges of diabetes foot care among patients with diabetes mellitus.</p><p><strong>Materials and methods: </strong>This descriptive cross-sectional study assessed knowledge and practice of foot care among type I and type II patients with diabetes attending the University of Benin Teaching Hospital, Benin City. The instrument for data collection was a structured questionnaire with a reliability of 0.880. SPSS version 22 was used to analyze the data.</p><p><strong>Results: </strong>The findings revealed that there is good knowledge of foot care, among 110 (50.0%) of the diabetic patients, while the practice of foot care was found to be poor among diabetic patients. It also shows the factor that statistically predicts the development of foot ulcers to include combined diet + oral medications + insulin treatment regimen (adjusted odds ratio [AOR] = 0.181, <i>P</i> = 0.016, confidence interval [CI] = 0.045-0.728), history of renal conditions (AOR = 0.115, <i>P</i> = 0.036, CI = 0.015-0.871), not receiving foot care education (AOR = 116.098, <i>P</i> < 0.001, CI = 12.497-1078.554), and receiving foot care education from nurses (AOR = 0.022, <i>P</i> = 0.001, CI = 0.002-0.216). Furthermore, 201 (91.4%) diabetes patients reported fatigue from completing the same task repeatedly, and 198 (90.0%) reported forgetfulness as obstacles to practicing foot care.</p><p><strong>Conclusion: </strong>When creating DM Patients future care plans, nurses and other health-care administrators must take into account the difficulties and predicting factors related to the practice of diabetes foot care.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Balchaturbhadra Churna as a potential medicine for SARS-CoV2 infection in pediatric setting an in silico study. 勘误:Balchaturbhadra Churna 作为治疗儿科 SARS-CoV2 感染的潜在药物的硅学研究。
Ayu
Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI: 10.4103/ayu.ayu_74_24

[This corrects the article on p. 146 in vol. 43.].

[这是对第 43 卷第 146 页文章的更正]。
{"title":"Erratum: Balchaturbhadra Churna as a potential medicine for SARS-CoV2 infection in pediatric setting an in silico study.","authors":"","doi":"10.4103/ayu.ayu_74_24","DOIUrl":"https://doi.org/10.4103/ayu.ayu_74_24","url":null,"abstract":"<p><p>[This corrects the article on p. 146 in vol. 43.].</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the anti-arthritic activity of Rhuflex-F - A proprietary Ayurvedic herbomineral formulation in albino rats. 对 Rhuflex-F - 一种阿育吠陀草药矿物专有配方在白化大鼠体内的抗关节炎活性进行评估。
Ayu
Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI: 10.4103/ayu.ayu_327_21
Veerendra Gupta, Balaji Panigrahi, Subrata De, Mukeshkumar B Nariya

Background: Rhuflex-F is a proprietary Ayurvedic herbo-mineral formulation clinically used to combat and relieve stiffness in joints and muscles, reduce edema, restore mobility, and also effective in relieving the symptoms of other autoimmune illnesses that lead to rheumatism.

Aims: The aim and objective of the research study is to evaluate the efficacy of Rhuflex-F against in vitro protein denaturation and in vivo Freund's adjuvant-induced arthritis in albino rats.

Materials and methods: In vitro inhibition of protein denaturation activity was carried out using bovine serum albumin. For in vivo activity, arthritis was induced by complete Freund's adjuvant in albino rats. Rhuflex-F (135-270 mg/kg, po) was administered for 30th days in arthritic rats, and effects were assessed on primary and secondary paw edema, on pain response, hematological, serum biochemical parameters (serum transaminases, alkaline phosphatase, urea, uric acid, and orosomucoid), and serum anti-oxidant parameters and adrenal ascorbic acid.

Results: Aqueous extract of Rhuflex-F showed in vitro protein denaturation inhibitory activity in a dose-dependent manner. Rhuflex-F showed nonsignificant decrease in primary and secondary paw edema with reduced pain response, some reversal effects on hematological parameters such as white blood cell and red blood cell related parameters and serum orosomucoid and adrenal ascorbic acid in comparison to Fruend's adjuvant control group. Further, Rhuflex-F reversed Freund's adjuvant-induced adverse effects on oxidant status in the serum of albino rats.

Conclusion: Result of the present study suggested that Rhuflex-F formulation has anti-inflammatory activity, may be due to the inhibition of protein denaturation in vitro and in vivo anti-arthritic activity against complete Freund's adjuvant-induced arthritis in albino rats.

背景:目的:本研究的目的和目标是评估 Rhuflex-F 对体外蛋白质变性和体内弗氏佐剂诱导的白化大鼠关节炎的疗效:使用牛血清白蛋白对蛋白质变性活性进行体外抑制。对于体内活性,则使用完全弗罗因德佐剂诱导白化大鼠关节炎。给关节炎大鼠服用 Rhuflex-F(135-270 毫克/千克,po)30 天,评估其对原发性和继发性爪水肿、疼痛反应、血液学、血清生化指标(血清转氨酶、碱性磷酸酶、尿素、尿酸和osomucoid)、血清抗氧化指标和肾上腺抗坏血酸的影响:结果:Rhuflex-F 的水提取物显示出体外蛋白质变性抑制活性,且呈剂量依赖性。与 Fruend 佐剂对照组相比,Rhuflex-F 能显著减轻原发性和继发性爪水肿,减轻疼痛反应,并能逆转血液学参数,如白细胞和红细胞相关参数、血清类橙皮苷和肾上腺抗坏血酸。此外,Rhuflex-F 还逆转了弗氏佐剂对白化大鼠血清氧化状态的不利影响:本研究结果表明,Rhuflex-F 制剂具有抗炎活性,这可能是因为它在体外抑制了蛋白质变性,在体内对完全弗氏佐剂诱导的白化大鼠关节炎具有抗关节炎活性。
{"title":"Evaluation of the anti-arthritic activity of Rhuflex-F - A proprietary Ayurvedic herbomineral formulation in albino rats.","authors":"Veerendra Gupta, Balaji Panigrahi, Subrata De, Mukeshkumar B Nariya","doi":"10.4103/ayu.ayu_327_21","DOIUrl":"https://doi.org/10.4103/ayu.ayu_327_21","url":null,"abstract":"<p><strong>Background: </strong>Rhuflex-F is a proprietary Ayurvedic herbo-mineral formulation clinically used to combat and relieve stiffness in joints and muscles, reduce edema, restore mobility, and also effective in relieving the symptoms of other autoimmune illnesses that lead to rheumatism.</p><p><strong>Aims: </strong>The aim and objective of the research study is to evaluate the efficacy of Rhuflex-F against <i>in vitro</i> protein denaturation and <i>in vivo</i> Freund's adjuvant-induced arthritis in albino rats.</p><p><strong>Materials and methods: </strong><i>In vitro</i> inhibition of protein denaturation activity was carried out using bovine serum albumin. For <i>in vivo</i> activity, arthritis was induced by complete Freund's adjuvant in albino rats. Rhuflex-F (135-270 mg/kg, po) was administered for 30<sup>th</sup> days in arthritic rats, and effects were assessed on primary and secondary paw edema, on pain response, hematological, serum biochemical parameters (serum transaminases, alkaline phosphatase, urea, uric acid, and orosomucoid), and serum anti-oxidant parameters and adrenal ascorbic acid.</p><p><strong>Results: </strong>Aqueous extract of Rhuflex-F showed <i>in vitro</i> protein denaturation inhibitory activity in a dose-dependent manner. Rhuflex-F showed nonsignificant decrease in primary and secondary paw edema with reduced pain response, some reversal effects on hematological parameters such as white blood cell and red blood cell related parameters and serum orosomucoid and adrenal ascorbic acid in comparison to Fruend's adjuvant control group. Further, Rhuflex-F reversed Freund's adjuvant-induced adverse effects on oxidant status in the serum of albino rats.</p><p><strong>Conclusion: </strong>Result of the present study suggested that Rhuflex-F formulation has anti-inflammatory activity, may be due to the inhibition of protein denaturation <i>in vitro</i> and <i>in vivo</i> anti-arthritic activity against complete Freund's adjuvant-induced arthritis in albino rats.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Kantakari Avaleha and its modified dosage form of Kantakari Avaleha granules in the management of bronchial asthma - An open-label randomized controlled clinical trial. Kantakari Avaleha 及其改良剂型 Kantakari Avaleha 颗粒剂治疗支气管哮喘的疗效--一项开放标签随机对照临床试验。
Ayu
Pub Date : 2022-07-01 Epub Date: 2023-10-09 DOI: 10.4103/ayu.AYU_311_20
U R S R K Senarthne, Mandip Goyal, Bishwajyoti Patgiri

Background: Bronchial asthma is a common chronic episodic respiratory disease that resemblance to Tamaka Shwasa in Ayurveda. Kantakari Avaleha is one of the primarily recommended formulations for the management of Shwasa (bronchial asthma), Kasa (cough), and Hikka (hiccup). Although Avaleha dosage forms are better medicaments, granules have an added advantage over them such as palatability, less moisture content, and easy handling. For this purpose, Kantakari Avaleha was modified into Kantakari Avaleha granules by modifying the operational procedures of Kantakari Avaleha.

Aims: To evaluate and compare the efficacy of Kantakari Avaleha and Kantakari Avaleha granules in the management of bronchial asthma.

Materials and method: A total of 69 patients with mild to moderate bronchial asthma were selected randomly and divided into groups A and B. Patients of groups A were treated with Kantakari Avaleha, whereas patients of groups B received Kantakari Avaleha granules. These dosage forms of Kantakari were given in the dose of six grams with lukewarm water before breakfast and dinner for 60 days and followed up for the next 30 days. Assessments were done before and after treatment as per the scoring patterns of international asthma guidelines of the Global Initiative for Asthma (GINA), Asthma Control Questionnaire (ACQ), Asthma Control Test (ACT), and Respiratory Rate (RR), Breath-Holding Time (BHT), Peak Expiratory Flow Volume (PEFV), and laboratory investigations such as complete blood count, liver and kidney function tests, and urine routine examination were also carried out. Paired t-test and Wilcoxon signed-rank test were applied to evaluate the effect of therapy in the individual group for the above-mentioned criteria. While the comparison of results between the groups was done by applying the coefficient of variation (CV).

Results: Group A showed better results in most of the cardinal symptoms, ACT, and ACQ, except for BHT, RR, and GINA control in terms of CV. In both the groups, statistically, highly significant improvement was found as per the overall assessment of bronchial asthma such as ACQ, ACT, and number of episodes and the difference between the groups was statistically insignificant.

Conclusion: Both dosage forms of Kantkari were found to be effective treatments for bronchial asthma with significant relieving capacity as internal use for over 2 months. Hence, Kantakari Avaleha granules could be substituted for Kantakari Avaleha.

背景:支气管哮喘是一种常见的慢性偶发性呼吸道疾病,在阿育吠陀中与 Tamaka Shwasa 相似。Kantakari Avaleha 是治疗 Shwasa(支气管哮喘)、Kasa(咳嗽)和 Hikka(打嗝)的主要推荐配方之一。虽然 Avaleha 的剂型是更好的药物,但颗粒剂比它们更有优势,如适口性好、含水量少和易于操作。目的:评估并比较 Kantakari Avaleha 和 Kantakari Avaleha 颗粒剂在治疗支气管哮喘方面的疗效:A 组患者接受 Kantakari Avaleha 治疗,B 组患者接受 Kantakari Avaleha 颗粒剂治疗。这些剂型的 Kantakari 均以 6 克的剂量在早餐和晚餐前用温水送服,持续 60 天,并在接下来的 30 天进行随访。治疗前后按照全球哮喘倡议(GINA)国际哮喘指南的评分模式、哮喘控制问卷(ACQ)、哮喘控制测试(ACT)、呼吸频率(RR)、屏气时间(BHT)、呼气峰流速(PEFV)进行了评估,还进行了实验室检查,如全血计数、肝肾功能检查和尿常规检查。根据上述标准,采用配对 t 检验和 Wilcoxon 符号秩检验来评价各组的治疗效果。组间结果比较采用变异系数(CV):结果:就变异系数而言,除 BHT、RR 和 GINA 控制外,A 组在大多数主要症状、ACT 和 ACQ 方面的效果更好。两组的 ACQ、ACT 和发作次数等支气管哮喘总体评估结果均有显著改善,组间差异无统计学意义:两种剂型的 Kantkari 均可有效治疗支气管哮喘,内服两个月以上可明显缓解症状。因此,可以用 Kantakari Avaleha 颗粒代替 Kantakari Avaleha。
{"title":"Efficacy of <i>Kantakari Avaleha</i> and its modified dosage form of <i>Kantakari Avaleha</i> granules in the management of bronchial asthma - An open-label randomized controlled clinical trial.","authors":"U R S R K Senarthne, Mandip Goyal, Bishwajyoti Patgiri","doi":"10.4103/ayu.AYU_311_20","DOIUrl":"https://doi.org/10.4103/ayu.AYU_311_20","url":null,"abstract":"<p><strong>Background: </strong>Bronchial asthma is a common chronic episodic respiratory disease that resemblance to <i>Tamaka Shwasa</i> in Ayurveda. <i>Kantakari Avaleha</i> is one of the primarily recommended formulations for the management of <i>Shwasa</i> (bronchial asthma), <i>Kasa</i> (cough), and <i>Hikka</i> (hiccup). Although <i>Avaleha</i> dosage forms are better medicaments, granules have an added advantage over them such as palatability, less moisture content, and easy handling. For this purpose, <i>Kantakari Avaleha</i> was modified into <i>Kantakari Avaleha</i> granules by modifying the operational procedures of <i>Kantakari Avaleha</i>.</p><p><strong>Aims: </strong>To evaluate and compare the efficacy of <i>Kantakari Avaleha</i> and <i>Kantakari Avaleha</i> granules in the management of bronchial asthma.</p><p><strong>Materials and method: </strong>A total of 69 patients with mild to moderate bronchial asthma were selected randomly and divided into groups A and B. Patients of groups A were treated with <i>Kantakari Avaleha</i>, whereas patients of groups B received <i>Kantakari Avaleha</i> granules. These dosage forms of <i>Kantakari</i> were given in the dose of six grams with lukewarm water before breakfast and dinner for 60 days and followed up for the next 30 days. Assessments were done before and after treatment as per the scoring patterns of international asthma guidelines of the Global Initiative for Asthma (GINA), Asthma Control Questionnaire (ACQ), Asthma Control Test (ACT), and Respiratory Rate (RR), Breath-Holding Time (BHT), Peak Expiratory Flow Volume (PEFV), and laboratory investigations such as complete blood count, liver and kidney function tests, and urine routine examination were also carried out. Paired <i>t</i>-test and Wilcoxon signed-rank test were applied to evaluate the effect of therapy in the individual group for the above-mentioned criteria. While the comparison of results between the groups was done by applying the coefficient of variation (CV).</p><p><strong>Results: </strong>Group A showed better results in most of the cardinal symptoms, ACT, and ACQ, except for BHT, RR, and GINA control in terms of CV. In both the groups, statistically, highly significant improvement was found as per the overall assessment of bronchial asthma such as ACQ, ACT, and number of episodes and the difference between the groups was statistically insignificant.</p><p><strong>Conclusion: </strong>Both dosage forms of <i>Kantkari</i> were found to be effective treatments for bronchial asthma with significant relieving capacity as internal use for over 2 months. Hence, <i>Kantakari Avaleha</i> granules could be substituted for <i>Kantakari Avaleha</i>.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138816223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the anti-hyperlipidemic effects of Triphala in high fat diet fed rats: Studies with two combinations. 评估 Triphala 对高脂饮食喂养大鼠的抗高血脂作用:两种组合的研究。
Ayu
Pub Date : 2022-07-01 Epub Date: 2023-10-09 DOI: 10.4103/ayu.AYU_74_19
Suman Rana, Princy Louis Palatty, Ruby Benson, Benson Mathai Kochikuzhyil, Manjeshwar Shrinath Baliga

Background: Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. Triphala, a polyherbal Ayurvedic formulation made from dried fruits of Haritaki (Terminalia chebula Retz.), Bibhitaki (Terminalia bellirica Roxb.), and Amalaki (Phyllanthus emblica Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, Triphala is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.

Aims: The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of Triphala against high fat diet induced-hyperlipidemia in rats.

Materials and method: Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of Haritaki, Bibhitaki, and Amalaki in ratio of 1:1:1 or 1:2:4, respectively) of Triphala (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.

Results: The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the Triphala combination and atorvastatin groups. Of the two groups of Triphala, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.

Conclusions: The results of the study indicate that of the two Triphala formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.

背景:高脂血症是冠心病和中风的主要危险因素之一:高脂血症是冠心病和中风的主要危险因素之一。Triphala是一种多草药阿育吠陀配方,由Haritaki(Terminalia chebula Retz.)、Bibhitaki(Terminalia bellirica Roxb.)和Amalaki(Phyllanthus emblica Gaertn.)的干燥果实制成,被认为有助于缓解高脂血症。在阿育吠陀经文中,根据患者的病情和体质,Triphala 以两种组合形式(1:1:1 和 1:2:4 的单个成分)之一配制和使用:用高脂肪饮食诱导 Spraque-Dawley 白化大鼠患高脂血症。同时给动物服用不同剂量的 Triphala(250、500 或 1000 毫克/千克体重)或阿托伐他汀组合(Haritaki、Bibhitaki 和 Amalaki 的组合,比例分别为 1:1:1 或 1:2:4)中的一种。动物在第 22 天被处死,并对血清进行脂质分析,对肝脏进行脂质过氧化分析。统计分析采用均值方差分析,然后进行 Dunnet 检验:结果表明,与安慰剂组相比,三苯氧胺联合用药组和阿托伐他汀组的血清总胆固醇和甘油三酯水平明显降低,而高密度脂蛋白胆固醇水平则有所上升。在两组三苯氧胺中,1:2:4 比例的配方优于 1:1:1。药物剂量最高(1000 毫克/千克体重)的 1:2:4 配方组在纠正高脂饮食引起的血脂异常方面优于阿托伐他汀,其动脉粥样硬化指数与阿托伐他汀相同:研究结果表明,在两种Triphala配方中,1:2:4比例的抗高血脂效果优于1:1:1比例的配方。
{"title":"Evaluation of the anti-hyperlipidemic effects of <i>Triphala</i> in high fat diet fed rats: Studies with two combinations.","authors":"Suman Rana, Princy Louis Palatty, Ruby Benson, Benson Mathai Kochikuzhyil, Manjeshwar Shrinath Baliga","doi":"10.4103/ayu.AYU_74_19","DOIUrl":"https://doi.org/10.4103/ayu.AYU_74_19","url":null,"abstract":"<p><strong>Background: </strong>Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. <i>Triphala</i>, a polyherbal Ayurvedic formulation made from dried fruits of <i>Haritaki</i> (<i>Terminalia chebula</i> Retz.), <i>Bibhitaki</i> (<i>Terminalia bellirica</i> Roxb.), and <i>Amalaki</i> (<i>Phyllanthus emblica</i> Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, <i>Triphala</i> is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.</p><p><strong>Aims: </strong>The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of <i>Triphala</i> against high fat diet induced-hyperlipidemia in rats.</p><p><strong>Materials and method: </strong>Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of <i>Haritaki</i>, <i>Bibhitaki</i>, and <i>Amalaki</i> in ratio of 1:1:1 or 1:2:4, respectively) of <i>Triphala</i> (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.</p><p><strong>Results: </strong>The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the <i>Triphala</i> combination and atorvastatin groups. Of the two groups of <i>Triphala</i>, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.</p><p><strong>Conclusions: </strong>The results of the study indicate that of the two <i>Triphala</i> formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138816224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-inflammatory activity of Atavijambira (Atalantia monophylla DC.) root and stem. Atavijambira (Atalantia monophylla DC.) 根和茎的抗炎活性。
Ayu
Pub Date : 2022-07-01 Epub Date: 2023-10-09 DOI: 10.4103/ayu.ayu_118_21
Das Ashokkumar Nathulal, Rabinarayan Acharya, Mukesh B Nariya

Background: Atalantia monophylla DC. family Rutaceae, a promising drug, has multifaceted ethnomedicinal claims to treat rheumatism, arthritis, paralysis, cough, skin diseases, etc., In traditional practice, root and stem are administered to treat rheumatism and arthritis, respectively.

Aim: The aim of this study was to evaluate the anti-inflammatory activity of the root and stem of A. monophylla against carrageenan-induced acute paw edema in wistar albino rats.

Materials and methods: Shade dried root and stem were grinded separately into a fine powder (120#) by the mechanical grinder. Test drugs were prepared in Phanta (hot infusion) form and used as fresh (A. monophylla root Phanta [AMRP] and A. monophylla stem Phanta [AMSP]). Difference between the groups was statistically determined by one-way ANOVA, followed by Dunnett's multiple "t" test for unpaired data.

Results: AMSP showed a significant decrease in paw inflammation at all-time interval (P < 0.05), whereas AMRP produced nonsignificant decrease in paw inflammation at 1 h (43.53%) and 5 h (25.74%) while significant (P < 0.05) anti-inflammatory activity at 3 h (36.35%) in comparison with the normal control group.

Conclusion: The present study concluded that A. monophylla stem is having significant anti-inflammatory activity in comparison to its root when administered in Phanta form against carrageenan-induced acute inflammation in rats.

背景:芸香科植物Atalantia monophylla DC.是一种很有前途的药物,具有治疗风湿病、关节炎、瘫痪、咳嗽、皮肤病等多方面的民族药用价值、目的:本研究旨在评估 A. monophylla 的根和茎对角叉菜胶诱导的急性爪水肿的抗炎活性:阴干的根和茎用机械研磨机分别研磨成细粉(120#)。试验药物以热灌肠形式制备,并作为新鲜药物使用(A. monophylla 根 Phanta [AMRP] 和 A. monophylla 茎 Phanta [AMSP])。各组之间的差异通过单因素方差分析进行统计,对非配对数据进行邓尼特多重 "t "检验:结果:与正常对照组相比,AMSP 在所有时间间隔内都能明显减轻爪部炎症(P < 0.05),而 AMRP 在 1 小时(43.53%)和 5 小时(25.74%)内减轻爪部炎症的效果不明显,但在 3 小时(36.35%)内具有明显的抗炎活性(P < 0.05):本研究得出的结论是,与根相比,A. monophylla 的茎在以 Phanta 形式给药时对角叉菜胶诱导的大鼠急性炎症具有显著的抗炎活性。
{"title":"Anti-inflammatory activity of <i>Atavijambira</i> (<i>Atalantia monophylla</i> DC.) root and stem.","authors":"Das Ashokkumar Nathulal, Rabinarayan Acharya, Mukesh B Nariya","doi":"10.4103/ayu.ayu_118_21","DOIUrl":"https://doi.org/10.4103/ayu.ayu_118_21","url":null,"abstract":"<p><strong>Background: </strong><i>Atalantia monophylla</i> DC. family Rutaceae, a promising drug, has multifaceted ethnomedicinal claims to treat rheumatism, arthritis, paralysis, cough, skin diseases, etc., In traditional practice, root and stem are administered to treat rheumatism and arthritis, respectively.</p><p><strong>Aim: </strong>The aim of this study was to evaluate the anti-inflammatory activity of the root and stem of <i>A. monophylla</i> against carrageenan-induced acute paw edema in wistar albino rats.</p><p><strong>Materials and methods: </strong>Shade dried root and stem were grinded separately into a fine powder (120#) by the mechanical grinder. Test drugs were prepared in <i>Phanta</i> (hot infusion) form and used as fresh (<i>A. monophylla</i> root <i>Phanta</i> [AMRP] and <i>A. monophylla</i> stem <i>Phanta</i> [AMSP]). Difference between the groups was statistically determined by one-way ANOVA, followed by Dunnett's multiple \"<i>t</i>\" test for unpaired data.</p><p><strong>Results: </strong>AMSP showed a significant decrease in paw inflammation at all-time interval (<i>P</i> < 0.05), whereas AMRP produced nonsignificant decrease in paw inflammation at 1 h (43.53%) and 5 h (25.74%) while significant (<i>P</i> < 0.05) anti-inflammatory activity at 3 h (36.35%) in comparison with the normal control group.</p><p><strong>Conclusion: </strong>The present study concluded that <i>A. monophylla</i> stem is having significant anti-inflammatory activity in comparison to its root when administered in <i>Phanta</i> form against carrageenan-induced acute inflammation in rats.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138816221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ayu
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1